Every material Form 8-K Lucid Diagnostics Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lucid Diagnostics received a Nasdaq notice on October 12, 2026, saying its common stock closed below the $1 minimum bid price for 30 consecutive business days through October 9, 2026. The company has until April 12, 2027 to regain compliance, and Nasdaq says the listing is not affected at this time, so shareholders can keep trading the stock under LUCD.
Nasdaq notice dated October 12, 2026 cites a closing bid price below $1 for 30 consecutive business days through October 9, 2026
Compliance period runs 180 calendar days, until April 12, 2027, and requires at least $1 for ten consecutive business days
Nasdaq says the notice has no effect on the listing now; common stock continues to trade as LUCD
Lucid Diagnostics said three public meetings in mid-September advanced payment, billing and coding pathways for its EsoGuard and EsoCheck tests. The filing reports no financial results, and the outcomes remain subject to final determinations, public comment periods and effective dates.
A CMS Medicare Advisory Panel meeting on September 15-16 recommended keeping EsoGuard's original gapfill payment basis under PLA code 0114U; CMS expects final determinations in November.
The AMA CPT Editorial Panel approved a new Category III CPT code for nonendoscopic esophageal cell collection on September 17-19.
Lucid says it will begin submitting Medicare claims this month for tests at its Texas lab, while claims from its California lab await a final revised LCD.
Lucid Diagnostics reported second quarter 2026 revenue of $1.5 million, up from $1.2 million a year earlier, and a GAAP net loss attributable to common stockholders of $14.7 million, or $(0.08) per share, compared with $7.9 million in the prior-year quarter. The company also said it secured its first laboratory benefit manager coverage policy for its EsoGuard test, but it still awaits a positive draft Medicare coverage policy.
Q2 2026 revenue was $1.5 million ($1,474 thousand), up from $1,163 thousand in Q2 2025.
GAAP net loss attributable to common stockholders was $14.7 million, or $(0.08) per share, versus $7.9 million a year earlier.
Non-GAAP adjusted loss was $10.9 million, or $(0.06) per share, versus $9.9 million in Q2 2025.
Cash and cash equivalents were $33.4 million at June 30, 2026, compared with $34.7 million at December 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lucid Diagnostics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →